The peer-reviewed study, published in the Cureus journal on Jan. 24, analyzed reports from the initial phase 3 trials of Pfizer and Moderna COVID-19 mRNA vaccines. These trials led to the shots being approved under Emergency Use Authorization (EUA) in the United States. The study also looked into several other research and reviews of the trials. It found that the vaccines had “dramatically lower” efficacy rates than the vaccine companies claimed.